ICD-10-CM code · FY2027
A04.2 Enteroinvasive Escherichia coli infection
BillableValid for claims as a specific diagnosis code
About A04.2
Ask EvidencePulse about bacterial intestinal infections
Answers from the published evidence, with every study linked. The question goes into the box; nothing is sent until you press Ask.
Coding notes for A04.2
No notes of its own; the notes below apply from the codes above it.
Also applies, from A04 Other bacterial intestinal infections
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Chapter 1 notes (apply to every code in it)
Includes Conditions this code covers.
- diseases generally recognized as communicable or transmissible
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- carrier or suspected carrier of infectious disease (Z22.-)
- certain localized infections - see body system-related chapters
- infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium (O98.-)
- infectious and parasitic diseases specific to the perinatal period (P35-P39)
- influenza and other acute respiratory infections (J00-J22)
Use additional code Add a second code for the detail named here.
- code to identify resistance to antimicrobial drugs (Z16.-)
Related codes in A04
- A04.0 Enteropathogenic Escherichia coli infectionBillable
- A04.1 Enterotoxigenic Escherichia coli infectionBillable
- A04.3 Enterohemorrhagic Escherichia coli infectionBillable
- A04.4 Other intestinal Escherichia coli infectionsBillable
- A04.5 Campylobacter enteritisBillable
- A04.6 Enteritis due to Yersinia enterocoliticaBillable
- A04.7 Enterocolitis due to Clostridium difficileHeader
- A04.8 Other specified bacterial intestinal infectionsBillable
- A04.9 Bacterial intestinal infection, unspecifiedBillable
Latest research on bacterial intestinal infections
- Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates
- 2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]
- Adjunct corticosteroids likely reduce short-term mortality in severe non-COVID-19 pneumonia
- Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea
- The 2 Minute Medicine Podcast Episode 39
More on bacterial intestinal infections from 2 Minute Medicine
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plans